ISPIRE Reports Strong Growth in Q2 FY2024: Operating Expenses Surge to $10.3 Million, Net Loss at $4 Million

Business by 2FIRSTS.ai
Feb.21.2024
ISPIRE Reports Strong Growth in Q2 FY2024: Operating Expenses Surge to $10.3 Million, Net Loss at $4 Million
ISPIRE reports significant revenue growth in Q2 of 2024, with total revenue reaching $41.7 million, driven by cannabis products.

According to the Nasdaq website on February 20th, the Nasdaq-listed company ISPIRE (NASDAQ: ISPR) announced its second quarter financial performance ending on December 31, 2023, and submitted its quarterly report on Form 10-Q on February 20, 2024.

ISPIRE Reports Strong Growth in Q2 FY2024: Operating Expenses Surge to $10.3 Million, Net Loss at $4 Million
Image source: NASDAQ

 

In the second quarter of the 2024 fiscal year, the company's revenue increased by 30.7% compared to the same period in 2023, reaching $41.7 million. Specifically, revenue from tobacco vaporization products was $22.1 million, and revenue from cannabis vaporization products was $19.5 million.

 

Gross profit also increased by 24.1% from $5.1 million in the same period in 2023 to $6.4 million. The gross profit margin decreased from 16.1% in the same period in 2023 to 15.3%.

 

However, total operating expenses increased by 114% from $4.8 million in the same period in 2023 to $10.3 million, resulting in a net loss of $4 million compared to a net loss of $100,000 in the same period in 2023.

 

Michael Wang, CEO of ISPIRE, commented that this quarter is crucial for product expansion and business operations. The company has undertaken several strategic initiatives, including obtaining ISO and GMP certifications for their Malaysian factory, and obtaining Pre-Market Tobacco Product Application (PMTA) approval in the United States. With a significant growth trend in sales related to their cannabis vaporizer hardware, they aim to further strengthen their presence in this market and expand their business scope.

 

Chief Financial Officer Daniel Machock added that in the second quarter of 2024, key growth indicators for Ispire highlighted the rapid expansion of the cannabis e-cigarette hardware business, with overall revenue increasing by 30% to $41.7 million, while cannabis e-cigarette hardware product sales grew by 149% year-on-year to $19.5 million.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

South Korea Expands Tobacco Harmful Components Testing System to Cover Synthetic Nicotine Liquid Vapes
South Korea Expands Tobacco Harmful Components Testing System to Cover Synthetic Nicotine Liquid Vapes
South Korea’s Ministry of Food and Drug Safety said on April 17 that it has additionally designated the International Characterization Research Institute as a tobacco harmful components testing body under the Act on the Management of Tobacco Harmfulness. The institute has research experience in analyzing harmful components in liquid e-cigarettes and has obtained recognition for tobacco-sector ISO 17025 requirements.
Apr.17 by 2FIRSTS.ai
Türkiye Records 4,163 E-Cigarette Smuggling Raids Over Five Years, With Seizures Worth TRY 1.84 Billion
Türkiye Records 4,163 E-Cigarette Smuggling Raids Over Five Years, With Seizures Worth TRY 1.84 Billion
Turkish Trade Minister Ömer Bolat disclosed enforcement figures on e-cigarette smuggling in response to a written parliamentary question. Over the past five years, Türkiye recorded 4,163 raids targeting e-cigarette smuggling, preventing illegal e-cigarettes, liquids and components worth TRY 1.84 billion, or about USD 40.68 million based on an exchange rate of USD 1 = TRY 45.2339, from reaching the market.
May.07 by 2FIRSTS.ai
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
FDA Center for Tobacco Products Acting Director Bret Koplow said at the American Tobacco and Nicotine Forum that the agency has reduced its premarket tobacco application backlog by about 70% over the past year and eliminated the acceptance queue. He said FDA has reviewed about 27 million applications, but only a small number have been authorized, mainly because most submissions lacked the scientific data needed to demonstrate public health benefits.
Apr.23 by 2FIRSTS.ai
Philippine Anti-Smoking Groups Urge DTI Action Over Alleged Vape Law Violations by ZYN and IQOS
Philippine Anti-Smoking Groups Urge DTI Action Over Alleged Vape Law Violations by ZYN and IQOS
Several anti-smoking and health advocacy groups in the Philippines urged the Department of Trade and Industry to take action against tobacco companies accused of violating the Vape Regulation Act of 2022. The groups said three consecutive complaints had been filed involving nicotine pouch brand ZYN and heated tobacco product company IQOS Philippines.
Apr.27 by 2FIRSTS.ai
 FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
The U.S. Food and Drug Administration (FDA) has initiated scientific review of renewal applications for 22nd Century Group’s VLN reduced-nicotine cigarettes under the Modified Risk Tobacco Product (MRTP) pathway, with current authorizations set to expire in December 2026.
News
May.13
Reuters: Big Tobacco Emerges as Winner After FDA Regulatory Shift
Reuters: Big Tobacco Emerges as Winner After FDA Regulatory Shift
According to Reuters, major tobacco companies may emerge as key beneficiaries after the U.S. FDA loosened regulations on vaping and nicotine pouch products, a shift that has sparked debate over public health risks.
Industry Insight
May.26